| Title | Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer |
| Authors | Zheng, Hong Shu, Tong Zhu, Shan Zhang, Chao Gao, Min Zhang, Nan Wang, Hongguo Yuan, Jie Tai, Zaixian Xia, Xuefeng Yi, Yuting Li, Jin Guan, Yanfang Xiang, Yang Gao, Yunong |
| Affiliation | Peking Univ, Dept Gynecol Oncol, Canc Hosp & Inst, Beijing, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China Geneplus Shenzhen, Shenzhen, Peoples R China Geneplus Beijing, Beijing, Peoples R China Xi An Jiao Tong Univ, Sch Elect & Informat Engn, Dept Comp Sci & Technol, Xian, Peoples R China |
| Keywords | HOMOLOGOUS RECOMBINATION GENES MUTATIONS BRCA1 CARBOPLATIN INSTABILITY EXPRESSION RESISTANCE OUTCOMES ABRAXAS |
| Issue Date | 16-Sep-2021 |
| Publisher | FRONTIERS IN ONCOLOGY |
| Abstract | Platinum-based chemotherapy is still the standard of care after cytoreductive surgery in the first-line treatment for epithelial ovarian cancer. This study aims to integrate novel biomarkers for predicting platinum sensitivity in EOC after initial cytoreductive surgery precisely. To this end, 60 patients were recruited from September 2014 to October 2019. Based on the duration of progress-free survival, 44 and 16 patients were assigned to platinum-sensitive and platinum-resistant group, respectively. Next generation sequencing was performed to dissect the genomic features of ovarian tumors obtained from surgery. Multiple genomic variations were compared between two groups, including single-nucleotide variant, single base or indel signature, loss of heterozygosity (LOH), whole-genome duplication (WGD), and others. The results demonstrated that patients with characteristics including positive SBS10a signature (p < 0.05), or FAM175A LOH (p < 0.01), or negative WGD (p < 0.01) were significantly enriched in platinum-sensitive group. Consistently, patients with positive SBS10a signature (15.8 vs. 10.1 months, p < 0.05), or FAM175A LOH (16.5 vs. 9.2 months, p < 0.05), or negative WGD (16.5 vs. 9.1 months, p < 0.05) have significantly longer PFS than those without these genetic features. By integrating these three biomarkers, a lasso regression model was employed to train and test for all patients, with the AUC value 0.864 in platinum sensitivity prediction. Notably, 388 ovarian cancer patients from TCGA dataset were leveraged as independent validation cohort with AUC value 0.808, suggesting the favorable performance and reliability of this model. |
| URI | http://hdl.handle.net/20.500.11897/629320 |
| ISSN | 2234-943X |
| DOI | 10.3389/fonc.2021.725264 |
| Indexed | SCI(E) |
| Appears in Collections: | 北京肿瘤医院 |
